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The present study aimed to investigate the binding affinity of andrographolide and its derivative i.e., 14-
deoxy-11,12-didehydroandrographolide with targets related to COVID-19 and their probable role in
regulating multiple pathways in COVID-19 infection. SMILES of both compounds were retrieved from the
PubChem database and predicted for probably regulated proteins. The predicted proteins were queried
in STRING to evaluate the protein–protein interaction, and modulated pathways were identified
concerning the KEGG database. Drug-likeness and ADMET profile of each compound was evaluated
using MolSoft and admetSAR 2.0, respectively. Molecular docking was carried using Autodock 4.0.
Andrographolide and its derivative were predicted to have a high binding affinity with papain-like
protease, coronavirus main proteinase, and spike protein. Molecular dynamics simulation studies were
performed for each complex which suggested the strong binding affinities of both compounds with
targets. Network pharmacology analysis revealed that both compounds modulated the immune system
by regulating chemokine signaling, Rap1 signaling, cytokine–cytokine receptor interaction, MAPK
signaling, NF-kappa B signaling, RAS signaling, p53 signaling, HIF-1 signaling, and natural killer cell-
mediated cytotoxicity. The study suggests strong interaction of andrographolide and 14-deoxy-11,12-
didehydroandrographolide against COVID-19 associated target proteins and exhibited different
immunoregulatory pathways.1. Introduction
In December 2019, a severe acute respiratory syndrome caused
by novel severe acute respiratory syndrome novel coronavirus 2
(SARS-CoV-2)1 emerged as a global pandemic from Wuhan city,
Hubei province, China. WHO designated this nSARS-CoV-2
infection as Coronavirus disease (COVID-19). The n-SARS-CoV-
2 is a highly contagious virus that can be transmitted from
person to person,2 leading to community transmission. COVID-
19 became a major global threat by inuencing around 212y, KLE College of Pharmacy Belagavi, KLE
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the Royal Society of Chemistrycountries, with almost half a million deaths worldwide.3 Pres-
ently, it has majorly affected subjects with comorbidities and
low immunity that are suffering from infectious and non-
infectious diseases.4 Patients with COVID-19, especially those
with severe pneumonia, showed substantially lower lymphocyte
counts, and severely ill patients exhibited a reduction in CD4+ T
cells, CD8+ T cells, and natural killer cells.5,6 The higher plasma
concentrations of several inammatory cytokines, such as IL-6
and tumor necrosis factor (TNF), were observed in COVID-19
patients.7 The pathological ndings in patients with COVID-19
showed that immune-mediated lung injury was involved in
acute respiratory distress syndrome (ARDS).8 This evidence
suggested an immune imbalance in COVID-19, and it was
contemplated that the immune modulation can provide some
prophylaxis and promising benet against COVID-19.9 Also,
there is a need to utilize the concept to identify the new thera-
peutic agent with immunomodulatory action and anti-viral
property against the COVID-19 as reported.10,11
The effectiveness of treatment based on traditional medicinal
plants has been reported during 2003 SARS.12–15 Therefore, the
scientic community has already started studies on medicinal
plants, based on their history and traditional uses, as plausible
leads in the treatment of COVID-19.3,16–20 For thousands of years,RSC Adv., 2021, 11, 5065–5079 | 5065

































































































View Article Onlinemedicinal plants have played a vital role in managing multiple
infectious and non-infectious diseases.21–23 Among them,
Andrographis paniculata (Family: Acanthaceae), also called known
as ‘King of bitters’ and ‘Indian Echinacea’ reserves its importance
in the management of various infectious and non-infectious
diseases.9,24–26 Further, it has been studied well for its potency
as a modulator of the immune system.25,27 In Andrographis pan-
iculata, andrographolide28 is a major bioactive that possesses
benecial effects in multiple pathogenic conditions, including
the immunity booster role.29 Further, two important databases,
i.e., ChEBI and PCIDB, also record andrographolide (Fig. 1) as
chief bioactive from Andrographis paniculata. Andrographolide
and its derivative(s) also exhibited decisive immunomodulatory
action25,27 and have broad-spectrum anti-viral properties.30
Further, it was found to be effective against multiple viral infec-
tions like dengue,31 swine u,32 hepatitis C,33 chikungunya,24
inuenza,34 Epstein–Barr virus (EBV)35 and herpes simplex virus 1
(HSV-1)36 in previous experimental studies. The andrographolide
derivative, i.e., 14-deoxy-11,12-didehydroandrographolide is one
of the major components/derivatives of A. paniculata reported for
its antiviral properties.37–39
Recently, andrographolide has been investigated as a potential
inhibitor of SARS-CoV-2 main protease (3CLpro) using an in-silico
approach.40 However, its potency to act over papain-like protease
(PLpro) and spike protein has not been investigated yet. Further,
there are numerous reports wherein various in silico approaches41
such as molecular docking, fast pulling of ligand (FPL), free energy
perturbation (FEP),42 density functional theory (DFT),43 high
throughput virtual screening,44 and drug repurposing studies45
have been exploited to investigate various target proteins of SARS-
COV-2. Likewise, there are recent reports of in-silico investigations
of murine natural products46 and some diverse scaffolds of
synthetic compounds designed through in silico insights.47,48 Since
the risk of getting an infection with COVID-19 is reported to be
higher in the subjects with compromised immunity,10 it is impor-
tant to consider in manipulating the immune system in them.
Hence, the present study aimed to investigate the prospective
potential of andrographolide and one of the major derivatives i.e.
14-deoxy-11,12-didehydroandrographolide as a potent anti-viral
agent by targeting three proteins of COVID-19, i.e., 3CLpro, PLpro,
and spike protein. Further, the study also evaluated the plausible
pathways to be regulated in enhancing the immune system.2. Materials and methods
2.1 Prediction of targets
SMILES of 14-deoxy-11,12-didehydroandrographolide and
andrographolide was retrieved from the PubChem (https://
pubchem.ncbi.nlm.nih.gov/) database49 and queried for5066 | RSC Adv., 2021, 11, 5065–5079protein-based prediction in DIGEP-Pred50 at a pharmacological
activity (Pa) > pharmacological inactivity (Pi).
2.2 Enrichment analysis
The list of up-and-down-regulated proteins was queried in the
STRING database.51 The biological process, cell component, and
molecular function were recorded. The modulated protein and
their associated pathways were identied using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway database.
The interaction between the compounds, their targets, and
pathways was constructed using Cytoscape (https://
cytoscape.org/) and was analyzed using “edge count” of
respective node.
2.3 In silico molecular docking
3D structures of 14-deoxy-11,12-didehydroandrographolide and
andrographolide were retrieved from the PubChem database in
.sdf format and converted into .pdb format using Discovery
studio 2019. The ligand of each molecule was minimized using
mmff94 forceeld and converted into ‘.pdbqt’ format. Structures
of 3CLpro (PDB: 6LU7) and PLpro (PDB: 4M0W) were retrieved
from the RCSB database,52 which were complexed with water
molecules and hetero atoms; removed using Discovery studio
2019 and saved in ‘.pdb’ format. The spike protein of coronavirus
was homology modeled target using accession number
AVP78042.1 as query sequence and PDB: 6VSB as a template
using SWISS-MODEL.53 Docking was carried using Autodock
4.0.54 Aer docking ten different ligand conformations were ob-
tained in which ligand possessing minimum binding energy was
chosen to visualize the ligand–protein interaction using
Discovery studio 2019.
2.4 Molecular dynamics (MD) simulation
MD simulations were carried out with the AMBER18 soware
package.55 The ligands 14-deoxy-11,12-didehydroandrograph-
olide and andrographolide were parameterized with ANTE-
CHAMBER56 employing GAFF force eld. The amino acid resi-
dues of each protein under study were parameterized with the
FF14SB force eld. The xLEAP program was used to prepare the
protein–ligand complexes of the target proteins 3CLpro, PLpro,
and spike protein with ligands' docked poses. Each protein–
ligand complex was solvated in a truncated octahedron of the
TIP3P box. Appropriate counter ions Na+ and Cl were added to
neutralize the system. Thus prepared, the protein–ligand
complexes were subjected to 100 ns MD simulations on Nvidia
V100-SXM2-16GB GPU using the PMEMD.CUDA module.
Initially, the system was subjected to energyminimization, where
water and the complete system were minimized in two steps.
Simulated annealing optimization, and the NVT and NPT equil-
ibration steps of 5 ns, each was performed to equilibrate the
system. The production phase MD simulations were performed
at 1 atm constant pressure using Monte Carlo barostat and 300 K
constant temperature by using Langevin thermostat. During the
simulation, a collision frequency of 2 ps1 and the volume
exchange was attempted for every 100 fs. Hydrogen bonds were
constrained by using the SHAKE algorithm, and the integration© 2021 The Author(s). Published by the Royal Society of Chemistry
Table 1 Regulated proteins by andrographolide and 14-deoxy-11,12-didehydroandrographolidea
Andrographolide 14-Deoxy-11,12-didehydroandrographolide
DownRegulation UpRegulation DownRegulation UpRegulation
Pa Pi Modulated proteins Pa Pi
Modulated
proteins Pa Pi Modulated proteins Pa Pi
Modulated
proteins
0.548 0.132 TOP2A 0.589 0.131 VDR 0.66 0.117 CHEK1 0.701 0.077 VDR
0.559 0.163 CHEK1 0.526 0.082 CD14 0.627 0.097 TOP2A 0.599 0.043 CD14
0.387 0.028 KRT16 0.336 0.079 CLU 0.562 0.041 IVL 0.47 0.045 CLU
0.364 0.038 KRT17 0.444 0.198 AR 0.451 0.016 KRT16 0.548 0.124 AR
0.331 0.026 PTH 0.417 0.175 ID1 0.445 0.025 KRT17 0.522 0.161 CD83
0.394 0.138 ESR2 0.231 0.043 RAP1A 0.379 0.015 PTH 0.459 0.131 ID1
0.297 0.076 TIMP2 0.375 0.197 RAC1 0.452 0.092 ESR2 0.483 0.178 NPPB
0.38 0.161 CCL2 0.32 0.17 GPX1 0.474 0.127 MDM2 0.429 0.152 RAC1
0.38 0.161 IVL 0.241 0.092 KLK2 0.444 0.097 CCL2 0.41 0.134 SMN2
0.306 0.142 LEP 0.394 0.257 NPPB 0.34 0.044 TIMP2 0.39 0.124 TNFRSF1A
0.364 0.212 PRKCA 0.319 0.186 TNFRSF1A 0.357 0.086 LEP 0.262 0.027 RAP1A
0.3 0.155 CCL4 0.31 0.191 KRT18 0.403 0.139 PRKCA 0.362 0.129 KRT18
0.27 0.141 IL6R 0.171 0.058 RXRA 0.328 0.107 CCL4 0.325 0.096 CTSB
0.226 0.138 GYPA 0.356 0.248 RARA 0.382 0.187 NR3C1 0.35 0.124 GPX1
0.349 0.269 MDM2 0.205 0.103 RHOB 0.299 0.105 IL6R 0.287 0.077 KLK2
0.319 0.28 NR3C1 0.178 0.095 RHOA 0.384 0.206 CASP8 0.412 0.209 PLAT
0.221 0.206 CD44 0.354 0.328 CD83 0.139 0.051 PTHLH 0.397 0.211 RARA
0.294 0.291 SMN2 0.247 0.166 CD44 0.371 0.201 CYP3A4
0.191 0.19 CD38 0.362 0.293 NOS2 0.322 0.162 FKBP5
0.276 0.229 FLT1 0.224 0.065 RHOB








































































































View Article Onlinestep of two fs was employed. Particle Mesh Ewald (PME) method
was used to compute the long-range electrostatic interactions,
while the cut-off of 8 Å was used to compute the short-range
interactions. The program CPPTRAJ was used to analyze the
interactions at every four ps on the result from the full trajectory.
The MD simulation results were analyzed in terms of RMSD and
RMSF of protein–ligand complexes.2.5 Calculation of drug-likeness and ADMET
The compound's drug-likeness was calculated based on the rule
of ve using Molso57 by querying the SMILES of compounds.
Further, absorption, distribution, metabolism, excretion and
toxicity (ADMET) prole were calculated using admetSAR2.0.583. Results
3.1 Prediction of targets
Andrographolide was predicted to regulate 36 proteins, of which
17 were down-regulated, and 19 were upregulated. Likewise, 14-
deoxy-11,12-didehydroandrographolide regulated 48 proteins in
which 21 were downregulated, and 27 were upregulated. The list
of regulated proteins with their Pa and Pi of both compounds is
summarized in Table 1.© 2021 The Author(s). Published by the Royal Society of Chemistry3.2 Enrichment analysis
A total of seventy-two different pathways were identied to be
regulated by the andrographolide, among which, pathways in
cancer were primarily regulated by modulating nine genes, i.e.,
AR, ESR2, IL6R, MDM2, PRKCA, RAC1, RARA, RHOA, RXRA at
the false discovery rate of 4.96 105. Similarly, 14-deoxy-11,12-
didehydroandrographolide was predicted to regulate seventy-
seven different pathways by modulating the Estrogen
signaling pathway via seven genes, i.e., ESR2, FKBP5, KRT16,
KRT17, KRT18, PGR, RARA at the false discovery rate of 7.57 
106. Pathways modulated by andrographolide and 14-deoxy-
11,12-didehydroandrographolide with their respective genes
are summarized in Tables 2 and 3, respectively.
Similarly, the interaction of both compounds with the
proteins and regulated pathways is represented in Fig. 2 and 3.
Further, the number of genes in multiple cellular compo-
nents, biological process, and molecular function for androgra-
pholide and 14-deoxy-11,12-didehydroandrographolide are
represented in Fig. 4 and5, respectively. Similarly, network
analysis of 14-deoxy-11,12-didehydroandrographolide identied
prime regulation of PRKCA protein and estrogen signaling
pathway. Further, andrographolide primarily modulated PRKCA
protein and pathways in cancer.RSC Adv., 2021, 11, 5065–5079 | 5067
Table 2 Enrichment analysis of andrographolide regulated targets







hsa05200 Pathways in cancer 9 4.96  105 AR, ESR2, IL6R, MDM2, PRKCA,
RAC1, RARA, RHOA, RXRA
hsa04640 Hematopoietic cell lineage 5 7.61  105 CD14, CD38, CD44, GYPA, IL6R
hsa04972 Pancreatic secretion 5 7.61  105 CD38, PRKCA, RAC1, RAP1A, RHOA
hsa05130 Pathogenic Escherichia coli infection 4 0.00014 CD14, KRT18, PRKCA, RHOA
hsa04915 Estrogen signaling pathway 5 0.00016 ESR2, KRT16, KRT17, KRT18, RARA
hsa04932 Non-alcoholic fatty liver disease (NAFLD) 5 0.00022 IL6R, LEP, RAC1, RXRA, TNFRSF1A
hsa04062 Chemokine signaling pathway 5 0.00048 CCL2, CCL4, RAC1, RAP1A, RHOA
hsa05205 Proteoglycans in cancer 5 0.00059 CD44, MDM2, PRKCA, RAC1, RHOA
hsa04015 Rap1 signaling pathway 5 0.00063 ID1, PRKCA, RAC1, RAP1A, RHOA
hsa04670 Leukocyte transendothelial migration 4 0.00091 PRKCA, RAC1, RAP1A, RHOA
hsa04071 Sphingolipid signaling pathway 4 0.00095 PRKCA, RAC1, RHOA, TNFRSF1A
hsa04060 Cytokine–cytokine receptor interaction 5 0.0013 CCL2, CCL4, IL6R, LEP, TNFRSF1A
hsa04961 Endocrine and other factor-regulated
calcium reabsorption
3 0.0013 KLK2, PRKCA, VDR
hsa05014 Amyotrophic lateral sclerosis (ALS) 3 0.0013 GPX1, RAC1, TNFRSF1A
hsa05418 Fluid shear stress and atherosclerosis 4 0.0013 CCL2, RAC1, RHOA, TNFRSF1A
hsa05206 MicroRNAs in cancer 4 0.0017 CD44, MDM2, PRKCA, RHOA
hsa04010 MAPK signaling pathway 5 0.0018 CD14, PRKCA, RAC1, RAP1A, TNFRSF1A
hsa04920 Adipocytokine signaling pathway 3 0.0024 LEP, RXRA, TNFRSF1A
hsa05152 Tuberculosis 4 0.0024 CD14, RHOA, TNFRSF1A, VDR
hsa05202 Transcriptional misregulation in cancer 4 0.0024 CD14, MDM2, RARA, RXRA
hsa05203 Viral carcinogenesis 4 0.0027 CHEK1, MDM2, RAC1, RHOA
hsa04151 PI3K-Akt signaling pathway 5 0.0031 IL6R, MDM2, PRKCA, RAC1, RXRA
hsa04510 Focal adhesion 4 0.0033 PRKCA, RAC1, RAP1A, RHOA
hsa05132 Salmonella infection 3 0.0035 CCL4, CD14, RAC1
hsa04064 NF-kappa B signaling pathway 3 0.0045 CCL4, CD14, TNFRSF1A
hsa04014 Ras signaling pathway 4 0.005 PRKCA, RAC1, RAP1A, RHOA
hsa04933 AGE-RAGE signaling pathway in
diabetic complications
3 0.005 CCL2, PRKCA, RAC1
hsa04620 Toll-like receptor signaling pathway 3 0.0052 CCL4, CD14, RAC1
hsa04659 Th17 cell differentiation 3 0.0052 IL6R, RARA, RXRA
hsa04722 Neurotrophin signaling pathway 3 0.0067 RAC1, RAP1A, RHOA
hsa04919 Thyroid hormone signaling pathway 3 0.0067 MDM2, PRKCA, RXRA
hsa04310 Wnt signaling pathway 3 0.0116 PRKCA, RAC1, RHOA
hsa04150 mTOR signaling pathway 3 0.0124 PRKCA, RHOA, TNFRSF1A
hsa04921 Oxytocin signaling pathway 3 0.0124 CD38, PRKCA, RHOA
hsa04530 Tight junction 3 0.0161 RAC1, RAP1A, RHOA
hsa05144 Malaria 2 0.0161 CCL2, GYPA
hsa05164 Inuenza A 3 0.0161 CCL2, PRKCA, TNFRSF1A
hsa04360 Axon guidance 3 0.0166 PRKCA, RAC1, RHOA
hsa04024 cAMP signaling pathway 3 0.0221 RAC1, RAP1A, RHOA
hsa04370 VEGF signaling pathway 2 0.0221 PRKCA, RAC1
hsa05169 Epstein–Barr virus infection 3 0.0221 CD38, CD44, MDM2
hsa04720 Long-term potentiation 2 0.0233 PRKCA, RAP1A
hsa04810 Regulation of actin cytoskeleton 3 0.0233 CD14, RAC1, RHOA
hsa05131 Shigellosis 2 0.0233 CD44, RAC1
hsa01524 Platinum drug resistance 2 0.0237 MDM2, TOP2A
hsa04115 p53 signaling pathway 2 0.0237 CHEK1, MDM2
hsa04520 Adherens junction 2 0.0237 RAC1, RHOA
hsa04664 Fc epsilon RI signaling pathway 2 0.0237 PRKCA, RAC1
hsa05100 Bacterial invasion of epithelial cells 2 0.0237 RAC1, RHOA
hsa05211 Renal cell carcinoma 2 0.0237 RAC1, RAP1A
hsa05214 Glioma 2 0.0237 MDM2, PRKCA
hsa05221 Acute myeloid leukemia 2 0.0237 CD14, RARA
hsa05223 Non-small cell lung cancer 2 0.0237 PRKCA, RXRA
hsa04918 Thyroid hormone synthesis 2 0.0239 GPX1, PRKCA
hsa05133 Pertussis 2 0.024 CD14, RHOA
hsa01521 EGFR tyrosine kinase inhibitor resistance 2 0.026 IL6R, PRKCA
hsa04350 TGF-beta signaling pathway 2 0.0287 ID1, RHOA
hsa05210 Colorectal cancer 2 0.0295 RAC1, RHOA
hsa04970 Salivary secretion 2 0.0297 CD38, PRKCA


































































































Table 2 (Contd. )







hsa04666 Fc gamma R-mediated phagocytosis 2 0.0311 PRKCA, RAC1
hsa05146 Amoebiasis 2 0.0339 CD14, PRKCA
hsa01522 Endocrine resistance 2 0.034 ESR2, MDM2
hsa05215 Prostate cancer 2 0.0348 AR, MDM2
hsa04066 HIF-1 signaling pathway 2 0.0349 IL6R, PRKCA
hsa05231 Choline metabolism in cancer 2 0.0349 PRKCA, RAC1
hsa05142 Chagas disease (American trypanosomiasis) 2 0.0358 CCL2, TNFRSF1A
hsa04668 TNF signaling pathway 2 0.0399 CCL2, TNFRSF1A
hsa04270 Vascular smooth muscle contraction 2 0.047 PRKCA, RHOA
hsa04110 Cell cycle 2 0.0492 CHEK1, MDM2
hsa04380 Osteoclast differentiation 2 0.0492 RAC1, TNFRSF1A
hsa04611 Platelet activation 2 0.0492 RAP1A, RHOA

































































































View Article Online3.3 In-silico molecular docking
Among andrographolide and 14-deoxy-11,12-
didehydroandrographolide, 14-deoxy-11,12-didehydroandro-
grapholide was predicted to have the highest binding affinity
with PLpro, i.e., 6.7 kcal mol1; however, it did not have any
hydrogen bond interactions. Similarly, andrographolide showed
6.5 kcal mol1 binding energy with PLpro with 1 hydrogen bond
interaction, i.e., Tyr274. Although both molecules had equal
binding energy with 3CLpro (6.8 kcal mol1), the number of
hydrogen bond interactions were more in andrographolide due to
interaction with Thr190, His163, and Cys145. Further, both
molecules showed a binding affinity with spike protein, i.e., 6.9
kcal mol1; however, andrographolide showed 1 hydrogen bond
interaction with Lys807 (Table 4).
The interaction of each compound with the respective
proteins is represented in Fig. 6.3.4 Molecular dynamics (MD) simulations
The exibility at the binding site and the desolvation mecha-
nism is not considered in the rigid docking methodology.
However, molecular dynamics simulations can provide deeper
insights into the interaction between ligand and protein amino
acid residues at the atomistic level. The integrated workow
comprising molecular docking and molecular dynamics simu-
lations is more suited in such situations as docking provides the
most favourable bioactive poses of inhibitor molecules. In
contrast, MD provides the insights of interactions and ener-
getics in a biological environment.59,60 The extended time scale
MD simulations allow exploring a vast space of conformational
optimization and its stability. In the present work, 100 ns MD
simulation of well-equilibrated systems was performed on the
complexes of 3CLpro, PLpro, and modeled spike protein, each of
which is bound to 14-deoxy-11,12-didehydroandrographolide
and andrographolide, respectively. The analysis of resulting
trajectories comprising of 10 000 frames provides insights into
the binding modes of inhibitor molecules, the formation of
hydrogen bonds, pi–pi interactions, van der Waals interactions,© 2021 The Author(s). Published by the Royal Society of Chemistryand the consequent stability of the system in terms of RMSD,
RMSF, and ligand-RMSD.
The MD trajectories of PLpro with 14-deoxy-11,12-
didehydroandrographolide and andrographolide were
analyzed for the protein RMSD, ligand RMSD and per residue
uctuations as RMSF (Fig. 7a–c). The RMSD analyses of PLpro
bound with 14-deoxy-11,12-didehydroandrographolide showed
a slight gradual increase in RMSD with initial equilibration at
around 2 Å for the rst 25 ns, aer which it had gradually risen
to 2.75 Å between 25 to 100 ns. These RMSD values point out the
system's stability and strong binding affinity between the PLpro
and the 14-deoxy-11,12-didehydroandrographolide molecule.
The subtle but gradual increase in RMSD could be attributed to
the binding site adaptation supported by the RMSF for the
binding site residues aa150 to aa200 and aa220 to aa240.
Interestingly, a similar trend in the RMSF was also observed in
the complex with andrographolide. These residues are present
at the binding cavity, and possibly they adopt the conformation
suitable for both the ligands. These RMSD uctuations in the
case of PLpro and andrographolide complex were observed,
reaching a maximum RMSD of 3 Å at around 85 ns. Aer that,
they were gradually decreasing to around 2.5 Å towards the end
of the simulation. The uctuations in RMSD may be in part due
to the C11–C12 rotatable bond, which may give rise to better
conformational exibility in the andrographolide molecule. The
Lig-RMSD of 14-deoxy-11,12-didehydroandrographolide
remains stable at 2.5 Å for about 75 ns and aer that uctu-
ates and sharply rises to 15 Å. However, the Lig-RMSD of
andrographolide remains stable at RMSD of 2.75 Å until 50 ns
and further rises to a stable RMSD of 5 Å until the end of the
simulation. The MD trajectories were visually inspected to
investigate the uctuations in Lig-RMSD (Fig. 7d and e). Both
the phytochemicals adopt a conformationally more stable
position by binding at the shallow binding cavity. Possibly
because the hydroxyl group at the 14th position in androgra-
pholide allows it to adopt a conformationally stable form
throughout the simulation; however, the lack of this hydroxyl
group and restricted rotation around the C11–C12 bond in 14-RSC Adv., 2021, 11, 5065–5079 | 5069
Table 3 Enrichment analysis of 14-deoxy-11,12-didehydroandrographolide regulated targets




rate Matching proteins in the network
hsa04915 Estrogen signaling pathway 7 7.57  106 ESR2, FKBP5, KRT16, KRT17, KRT18, PGR, RARA
hsa05200 Pathways in cancer 11 7.57  106 AR, CASP8, ESR2, IL6R, MDM2, NOS2,
PRKCA, RAC1, RARA, RHOA, RXRA
hsa05202 Transcriptional misregulation in cancer 7 1.32  105 CD14, FLT1, MDM2, PLAT, PLAU, RARA, RXRA
hsa04932 Non-alcoholic fatty liver disease (NAFLD) 6 9.13  105 CASP8, IL6R, LEP, RAC1, RXRA, TNFRSF1A
hsa04972 Pancreatic secretion 5 0.00016 CD38, PRKCA, RAC1, RAP1A, RHOA
hsa05152 Tuberculosis 6 0.00016 CASP8, CD14, NOS2, RHOA, TNFRSF1A, VDR
hsa04015 Rap1 signaling pathway 6 0.00023 FLT1, ID1, PRKCA, RAC1, RAP1A, RHOA
hsa05014 Amyotrophic lateral sclerosis (ALS) 4 0.00023 CAT, GPX1, RAC1, TNFRSF1A
hsa05130 Pathogenic Escherichia coli infection 4 0.00023 CD14, KRT18, PRKCA, RHOA
hsa05205 Proteoglycans in cancer 6 0.00023 CD44, MDM2, PLAU, PRKCA, RAC1, RHOA
hsa05418 Fluid shear stress and atherosclerosis 5 0.00035 CCL2, PLAT, RAC1, RHOA, TNFRSF1A
hsa05206 MicroRNAs in cancer 5 0.00054 CD44, MDM2, PLAU, PRKCA, RHOA
hsa04060 Cytokine–cytokine receptor interaction 6 0.00065 CCL2, CCL4, FLT1, IL6R, LEP, TNFRSF1A
hsa04610 Complement and coagulation cascades 4 0.00065 CLU, PLAT, PLAU, PROS1
hsa05132 Salmonella infection 4 0.00075 CCL4, CD14, NOS2, RAC1
hsa04010 MAPK signaling pathway 6 0.00095 CD14, FLT1, PRKCA, RAC1, RAP1A, TNFRSF1A
hsa04062 Chemokine signaling pathway 5 0.00095 CCL2, CCL4, RAC1, RAP1A, RHOA
hsa04064 NF-kappa B signaling pathway 4 0.00095 CCL4, CD14, PLAU, TNFRSF1A
hsa04066 HIF-1 signaling pathway 4 0.00095 FLT1, IL6R, NOS2, PRKCA
hsa04640 Hematopoietic cell lineage 4 0.00095 CD14, CD38, CD44, IL6R
hsa05203 Viral carcinogenesis 5 0.00095 CASP8, CHEK1, MDM2, RAC1, RHOA
hsa05215 Prostate cancer 4 0.00095 AR, MDM2, PLAT, PLAU
hsa04510 Focal adhesion 5 0.00097 FLT1, PRKCA, RAC1, RAP1A, RHOA
hsa04620 Toll-like receptor signaling pathway 4 0.00097 CASP8, CCL4, CD14, RAC1
hsa05142 Chagas disease (American trypanosomiasis) 4 0.00097 CASP8, CCL2, NOS2, TNFRSF1A
hsa04670 Leukocyte transendothelial migration 4 0.0013 PRKCA, RAC1, RAP1A, RHOA
hsa04071 Sphingolipid signaling pathway 4 0.0014 PRKCA, RAC1, RHOA, TNFRSF1A
hsa04151 PI3K-Akt signaling pathway 6 0.0014 FLT1, IL6R, MDM2, PRKCA, RAC1, RXRA
hsa04014 Ras signaling pathway 5 0.0015 FLT1, PRKCA, RAC1, RAP1A, RHOA
hsa04961 Endocrine and other factor-regulated
calcium reabsorption
3 0.0015 KLK2, PRKCA, VDR
hsa04115 p53 signaling pathway 3 0.004 CASP8, CHEK1, MDM2
hsa04920 Adipocytokine signaling pathway 3 0.004 LEP, RXRA, TNFRSF1A
hsa01524 Platinum drug resistance 3 0.0041 CASP8, MDM2, TOP2A
hsa04621 NOD-like receptor signaling pathway 4 0.0041 CASP8, CCL2, CTSB, RHOA
hsa05133 Pertussis 3 0.0045 CD14, NOS2, RHOA
hsa05146 Amoebiasis 3 0.0085 CD14, NOS2, PRKCA
hsa04933 AGE-RAGE signaling pathway
in diabetic complications
3 0.0093 CCL2, PRKCA, RAC1
hsa04659 Th17 cell differentiation 3 0.0101 IL6R, RARA, RXRA
hsa04668 TNF signaling pathway 3 0.0115 CASP8, CCL2, TNFRSF1A
hsa05145 Toxoplasmosis 3 0.0115 CASP8, NOS2, TNFRSF1A
hsa04215 Apoptosis – multiple species 2 0.0127 CASP8, TNFRSF1A
hsa04722 Neurotrophin signaling pathway 3 0.0127 RAC1, RAP1A, RHOA
hsa04919 Thyroid hormone signaling pathway 3 0.0127 MDM2, PRKCA, RXRA
hsa04210 Apoptosis 3 0.0188 CASP8, CTSB, TNFRSF1A
hsa04310 Wnt signaling pathway 3 0.0215 PRKCA, RAC1, RHOA
hsa04150 mTOR signaling pathway 3 0.0231 PRKCA, RHOA, TNFRSF1A
hsa04921 Oxytocin signaling pathway 3 0.0231 CD38, PRKCA, RHOA
hsa04530 Tight junction 3 0.0306 RAC1, RAP1A, RHOA
hsa05134 Legionellosis 2 0.0306 CASP8, CD14
hsa05164 Inuenza A 3 0.0306 CCL2, PRKCA, TNFRSF1A
hsa05416 Viral myocarditis 2 0.0308 CASP8, RAC1
hsa04360 Axon guidance 3 0.0311 PRKCA, RAC1, RHOA
hsa04370 VEGF signaling pathway 2 0.0327 PRKCA, RAC1
hsa04020 Calcium signaling pathway 3 0.0328 CD38, NOS2, PRKCA
hsa05168 Herpes simplex infection 3 0.0332 CASP8, CCL2, TNFRSF1A
hsa05167 Kaposi's sarcoma-associated
herpesvirus infection
3 0.0335 CASP8, RAC1, TNFRSF1A
hsa05131 Shigellosis 2 0.0343 CD44, RAC1
hsa04720 Long-term potentiation 2 0.0347 PRKCA, RAP1A


































































































Table 3 (Contd. )




rate Matching proteins in the network
hsa04024 cAMP signaling pathway 3 0.0362 RAC1, RAP1A, RHOA
hsa04664 Fc epsilon RI signaling pathway 2 0.0362 PRKCA, RAC1
hsa05169 Epstein–Barr virus infection 3 0.0362 CD38, CD44, MDM2
hsa05211 Renal cell carcinoma 2 0.0362 RAC1, RAP1A
hsa05214 Glioma 2 0.0362 MDM2, PRKCA
hsa05221 Acute myeloid leukemia 2 0.0362 CD14, RARA
hsa05223 Non-small cell lung cancer 2 0.0362 PRKCA, RXRA
hsa04520 Adherens junction 2 0.037 RAC1, RHOA
hsa04810 Regulation of actin cytoskeleton 3 0.037 CD14, RAC1, RHOA
hsa04918 Thyroid hormone synthesis 2 0.037 GPX1, PRKCA
hsa04976 Bile secretion 2 0.037 CYP3A4, RXRA
hsa05100 Bacterial invasion of epithelial cells 2 0.037 RAC1, RHOA
hsa01521 EGFR tyrosine kinase inhibitor resistance 2 0.0409 IL6R, PRKCA
hsa04146 Peroxisome 2 0.0433 CAT, NOS2
hsa04350 TGF-beta signaling pathway 2 0.0446 ID1, RHOA
hsa05323 Rheumatoid arthritis 2 0.045 CCL2, FLT1
hsa05210 Colorectal cancer 2 0.0454 RAC1, RHOA
hsa04970 Salivary secretion 2 0.0457 CD38, PRKCA

































































































View Article Onlinedeoxy-11,12-didehydroandrographolide may be responsible for
larger uctuations in Lig-RMSD aer 75 ns. The residues Val164
and Tyr274 participate in hydrogen bond formation with
a carbonyl oxygen atom at C16 position in both the ligands.
These bonds break in 14-deoxy-11,12-
didehydroandrographolide more oen aer 75 ns due to
restricted rotation around the C11–C12 bond. The ligand
superposition also shows some structural conformational
changes in both the ligands. The MDS studies on the PLpro–
ligand complexes suggest that these complexes are relatively
stable.Fig. 2 Interaction of andrographolide with the proteins and regulated p
© 2021 The Author(s). Published by the Royal Society of ChemistryThe MDS trajectories of 3CLpro bound to each ligand were
analyzed, and the protein RMSD, ligand RMSD and per amino
acid residue uctuations, RMSF were recorded (Fig. 8a–c). The
protein RMSD for the 14-deoxy-11,12-didehydroandro-
grapholide rise to about 3 Å during the rst 25 ns and then
equilibrated at around 3 Å until 75 ns, aer which it uctuates
and rose to around 4.5 Å towards the end of MDS. On the other
hand, the andrographolide bound to 3CLpro equilibrates
quickly, and the RMSD remains in 2 to 3 Å throughout the
simulation. It indicates the fair stability of 3CLpro bound to
andrographolide. This nding is also clearly reected in the
RMSF and ligand RMSD. The ligand RMSD of andrographolideathways.
RSC Adv., 2021, 11, 5065–5079 | 5071

































































































View Article Onlineis fairly constant to 2 Å until 40 ns of the MDS, increasing
slightly to 2.5 Å aer that and equilibrated in the same
conformation for the rest of the MDS. 14-deoxy-11,12-
didehydroandrographolide equilibrate initially with RMSD ofFig. 4 GO enrichment analysis for andrographolide. (a) cellular compon
5072 | RSC Adv., 2021, 11, 5065–50792 Å till 25 ns, and there is steep conformational change result-
ing in RMSD of 2.5 Å till around 70 ns.
Larger uctuations in the RMSD were observed aer 70 ns
with an increase in RMSD to an average of around 7.5 Å. Theent, (b) molecular function, and (c) biological process.
© 2021 The Author(s). Published by the Royal Society of Chemistry


































































































View Article Onlineresults of ligand RMSD indicates better conformational stability
of andrographolide than 14-deoxy-11,12-didehydroandro-
grapholide (Fig. 8b). The per residue RMSF for both the
complexes has a similar pattern of uctuating residues
involvement with the uctuations ranging between 0.5 to 4 Å;
however, the RMSF values for 14-deoxy-11,12-
didehydroandrographolide are slightly higher than androgra-
pholide. The residues aa48–aa52 and aa150–aa200 clearly show
larger deviations in RMSF with 14-deoxy-11,12-
didehydroandrographolide (Fig. 8c). A visual analysis of the
MDS trajectories was performed to ascertain these observations,Table 4 Docking hits of andrographolide and 14-deoxy-11,12-didehydr
Targets Ligand
PLpro (PDB 4M0W) 14-Deoxy-11,12-didehydroandrographolide
Andrographolide




© 2021 The Author(s). Published by the Royal Society of Chemistryas shown in Fig. 8d and e. In the initial conformation of 14-
deoxy-11,12-didehydroandrographolide bound to 3CLpro before
MDS, a hydrogen bond between the carbonyl oxygen at C14 and
Arg131 residue of the active site was observed. However, this
hydrogen bond breaks and new hydrogen bonds were formed
with other residues such as Gln109 and Thr190. Probably due to
conformationally restricted bond rotation around C11–C12,
these hydrogen bonds are formed less frequently, which is
evident in RMSF values in these residues and ligand RMSD
(Fig. 8d). In the case of andrographolide bound to 3CLpro, the
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Fig. 6 Docked poses of ligands at the binding site of each protein. Hydrogen bond donor and acceptor regions are shown as the surface around
the binding site. (1) Binding site of papain-like protease (PLpro) (PDB:4M0W), (2) binding site of 3CLpro (PDB:6LU7), and (3) spike protein (panel
a represents 14-deoxy-11,12-didehydroandrographolide and panel b represents andrographolide).
Fig. 7 Trajectory analysis for PLpro (PDB: 4M0W) bound to 14-deoxy-11,12-didehydroandrographolide and andrographolide; (a) root mean
square deviation (RMSD), (b) root mean square deviation for each ligand (Lig-RMSD), and (c) root mean square fluctuations per amino acid (aa)
(RMSF). Interaction analysis of the PLpro bound to ligands during themolecular dynamics simulation; (d) equilibrated structure of 14-deoxy-11,12-
didehydroandrographolide bound to the PLpro before MDS production phase (green) and post-MDS production phase (red); (e) equilibrated
structure of andrographolide bound to the PLpro before MDS production phase (green) and post-MDS production phase (red).


































































































Fig. 9 Trajectory analysis for modeled spike protein bound to 14-deoxy-11,12-didehydroandrographolide and andrographolide; (a) root mean
square deviation (RMSD), (b) root mean square deviation for each ligand (Lig-RMSD), and (c) root mean square fluctuations per amino acid (aa)
(RMSF). Interaction analysis of the 3CLpro bound to ligands during the molecular dynamics simulation; (d) equilibrated structure of 14-deoxy-
11,12-didehydroandrographolide bound to the spike protein before MDS production phase (green) and post-MDS production phase (red); (e)
equilibrated structure of andrographolide bound to the spike protein before MDS production phase (green) and post-MDS production phase
(red).
Fig. 8 Trajectory analysis for 3CLpro (PDB: 6LU7) bound to 14-deoxy-11,12-didehydroandrographolide and andrographolide; (a) root mean
square deviation (RMSD), (b) root mean square deviation for each ligand (Lig-RMSD), and (c) root mean square fluctuations per amino acid (aa)
(RMSF). Interaction analysis of the 3CLpro bound to ligands during the molecular dynamics simulation; (d) equilibrated structure of 14-deoxy-
11,12-didehydroandrographolide bound to the 3CLpro before MDS production phase (green) and post-MDS production phase (red); (e) equili-
brated structure of andrographolide bound to the 3CLpro before MDS production phase (green) and post-MDS production phase (red).






































































































Molecular formula C20H30O5 C20H28O4
Molecular weight 350.21 332.20
Number of HBA 5 4
Number of HBD 3 2
Mollog P 2.19 3.09
Mollog S log (mol L1) 1.97 2.67
mg L1 3791.12 702.11
MolPSA (A2) 71.27 55.16
MolVol (A3) 416.03 421.79
Number of stereocenters 6 5

































































































View Article Onlinecarbonyl oxygen–His163, C14-hydroxyl group oxygen–Cys145,
and C19-hydroxyl oxygen–Thr190. During MDS's progress, some
of these hydrogen bonds break, and new hydrogen bonds were
formed with adjacent residues such as Ala191 and His164.
However, due to conformational exibility in andrographolide
around the C11–C12 bond, the ligand stabilizes and quickly
gains an energetically lower conformation (Fig. 8e). These
observations suggest conformationally better stabilization of
the andrographolide at the binding site of 3CLpro.Fig. 10 ADMET profile of (A) andrographolide, and (B) 14-deoxy-
11,12-didehydroandrographolide.
5076 | RSC Adv., 2021, 11, 5065–5079The MDS trajectories of modelled spike protein bound to
both the ligands were analyzed. The protein RMSD, ligand
RMSD and per amino acid residue uctuations, and RMSF were
recorded (Fig. 9a–c). The RMSD in spike protein bound to each
ligand shows uctuations in the range 5 to 12 Å, and it is
acceptable due to the amino acid composition of the protein
comprising more than 600 residues. In spike protein bound to
14-deoxy-11,12-didehydroandrographolide, an initial increase
in RMSD to 10 Å till 25 ns simulation was observed, which
remained stable with minor deviations, thereaer till the end of
simulation with RMSD of 10 Å. This suggests the conforma-
tional stability of 14-deoxy-11,12-didehydroandrographolide at
the binding cavity, which resulted in the system stability.
On the other hand, spike protein bound with andrographo-
lide showed a similar trend in RMSD initially till 25 ns, which
rises to around 12.5 Å during 25 ns to 100 ns. The binding site
residues undergo conformational change during this simula-
tion period. Possibly, the conformational change in the residues
is due to conformational exibility in the andrographolide
molecule. The ligand RMSD and per residue RMSF supports
this observation for andrographolide (Fig. 9b and c). The ligand
RMSD of andrographolide increases sharply during initial MDS
to around 15 Å until 25 ns and decreases to around 5 Å until 50
ns. However, it is unable to converge to a stable RMSD aer that
which suggests the major conformational changes in androg-
rapholide and, consequently, the conformational changes in
the binding site.
In contrast, the RMSD uctuations in 14-deoxy-11,12-
didehydroandrographolide are very subtle, with an initial rise
to around 5 Å, and remain stable at this RMSD with minor
deviations through the rest of the simulation period, suggests
a stable complex and strong binding between the protein and
ligand. The RMSF in spike protein residues also supports these
observations. The residues aa300–aa550 clearly shows larger
deviations in RMSF of around 7 to 12 Å with andrographolide
(Fig. 9b). Most of these residues belong to the binding cavity.
The corresponding RMSF values in the case of 14-deoxy-11,12-
didehydroandrographolide for these residues range from 5 to
7 Å. A visual analysis of the MDS trajectories was also performed

































































































View Article Onlineconformation of 14-deoxy-11,12-didehydroandrographolide
bound to spike protein has a hydrogen bond between the
carbonyl oxygen at C14 and Tyr585 and C19-hydroxyl group
oxygen and Pro263. However, these hydrogen bond breaks and
a new hydrogen bond were formed between the C14 carbonyl
oxygen and Trp582. In the case of andrographolide bound to
spike protein, the initial equilibrated conformation shows
a hydrogen bond between C3 hydroxyl group hydrogen and
Asn285 and Gln282 residues. Due to conformational exibility
in andrographolide, during the production phase of MDS, these
hydrogen bonds break. However, no new hydrogen bond
formation was observed towards the end of the simulation.3.5 Drug-likeness and ADMET proling
14-Deoxy-11,12-didehydroandrographolide scored higher drug-
likeness score, i.e., 0.52 compared to andrographolide,
which was computed based on molecular weight, number of
hydrogen bond donor, number of hydrogen bond acceptor, and
log P value (Table 5). It has inuenced both compounds' phar-
macokinetic characters by affecting absorption, distribution,
metabolism, excretion, and toxicity (Fig. 10).4. Discussion
The present study investigated one of the active biomolecules,
andrographolide, and its derivative i.e., 14-deoxy-11,12-
didehydroandrographolide from Andrographis paniculate, for
the regulation of the proteins/immunomodulatory pathways
and also assess their binding affinity with three targets, i.e.,
3CLpro, PLpro, and spike protein involved in the COVID infec-
tion. Further, we investigated the drug-likeness property of both
molecules in which andrographolide scored a lower drug-
likeness character compared to 14-deoxy-11,12-didehydroan-
drographolide. However, on looking at the binding affinity and
number of hydrogen bond interactions, andrographolide
showed a higher interaction towards the selected targets. It
suggests fewer modications could be made in the androgra-
pholide moiety to enhance its drug-likeness property without
altering the binding affinity towards the targeted proteins.
Further, some modications could be made in 14-deoxy-11,12-
didehydroandrographolide to amplify the hydrogen bond
interaction and eventually increase the higher binding affinity
with targeted proteins.
Subjects with lower immunity system are more prone to
infection with COVID 19 due to compromised immunity
system,61 which is well proven in subjects suffering from an
infectious and non-infectious disease(s). In this case, it is crucial
to enhance the subjects' immunity tominimize the probability of
viral infection. In the present study, via the enrichment analysis,
we identied multiple pathways involved in boosting the
immune system, which ismodulated by andrographolide and 14-
deoxy-11,12-didehydroandrographolide.
In the present study, we identied potential modulation of
few pathways, directly or indirectly linked with the modulation of
the immune system, i.e., chemokine signaling pathway, Rap1
signaling pathway, cytokine–cytokine receptor interaction, MAPK© 2021 The Author(s). Published by the Royal Society of Chemistrysignaling pathway, NF-kappa B signaling pathway, RAS signaling
pathway, p53 signaling pathway, HIF-1 signaling pathway, and
natural killer cell-mediated cytotoxicity. Among the above path-
ways, chemokine signaling pathways, Rap1 signaling pathway,
and cytokine–cytokine receptor interaction are the choice of
interest pathways as they are directly linked with the immune
system's regulation, and they scored minimum false discovery
rate compared to the rest of the pathways. The chemokine
signaling pathway was modulated by andrographolide and 14-
deoxy-11,12-didehydroandrographolide, which could control the
migration of immune cells in tissues.62 Further, the Rap1
signaling pathway is involved in activating three secondary
messengers, i.e., cAMP, calcium, and diacylglycerol,63 which are
needed in the signaling of cell position during viral infections;
modulated by andrographolide by regulating ID1, PRKCA, RAC1,
RAP1A, and RHOA and by 14-deoxy-11,12-
didehydroandrographolide by regulating FLT1, ID1, PRKCA,
RAC1, RAP1A, and RHOA. Similarly, the KEGG database has
recorded cytokine–cytokine receptor interaction as an entry
(hsa04060) in various auto-immune disorders. Since COVID-19
has a more risk over the infections on the altered immune
system of subjects, modulation of this pathway could be bene-
cial in them, modulated by andrographolide and 14-deoxy-11,12-
didehydroandrographolide. Further, the MAPK signaling
pathway has been identied to play an essential role in the
functioning of T lymphocytes,64 was observed to be modulated by
andrographolide and 14-deoxy-11,12-didehydroandrographolide.
Additionally, other pathways like NF-kappa B signaling pathway,
ras signaling pathway, p53 signaling pathway, HIF-1 signaling
pathway, and natural killer cell-mediated cytotoxicity are also
regulated which has been well reported to be involved in the
modulation of the immune system.
In COVID-19 infection, the n-CoV-2 binds to ACE-2, enters
into the cell, and starts deregulating the intracellular functions
by altering the normal homeostatic stimulus.65 Hence, it is
needed to control the components by binding over them or
responding towards the stimulus 3CLpro, or at least to minimize
its effect by controlling the intracellular cascade initiated by the
viral infection. Further, gene ontology enrichment analysis
identied andrographolide and 14-deoxy-11,12-
didehydroandrographolide to target the intracellular compo-
nents, binding capacity towards various proteins as a molecular
function and responder towards stimulus which could be the
possible action of these two agents over the viral infection.
A concept of modulation of multiple proteins by a single
molecule is the choice of research interest in identifying the
lead hit towards respective targets. Further, andrographolide
has been previously reported to possess anti-viral properties.29
Hence, based on the same concept, andrographolide and 14-
deoxy-11,12-didehydroandrographolide may also possess the
anti-viral efficacy over COVID-19, which kindled us evaluating
the binding affinity of these bioactives over PLpro, 3CLpro, and
spike protein. Although the drug-likeness score model pre-
dicted 14-deoxy-11,12-didehydroandrographolide to behave like
a drug based on “Rule of Five”, the binding affinity and number

































































































View Article Onlinemore on three proteins of COVID-19 i.e. PLpro, 3CLpro, and spike
protein.5. Conclusion
The present study utilized the system biology approach to
investigate the andrographolide and 14-deoxy-11,12-didehy-
droandrographolide against COVID-19 by modulating the
multiple pathways in which the chemokine signaling pathway
could be a choice of interest as it is directly linked in modulating
the immune response and scored the lowest false discovery rate.
Further, andrographolide could possess higher importance than
14-deoxy-11,12-didehydroandrographolide as it scored higher
interaction with the targeted proteins of COVID-19. However, the
present ndings are completely based on computer simulations
and database query; the outcome may vary based on processing
units and database updates; suggests the necessity to conrm the
present ndings via well-designed experimental protocols and is
the future scope of present ndings.Author contributions
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